Opendata, web and dolomites
  1. home
  2. trasparenza
  3. open h2020
  4. it4b-all

IT4B-ALL SIGNED

Therapeutic immunotherapy targeting NG2 and CD22 antigens for MLL-rearranged and MLL-germline B-cell Acute Lymphoblastic Leukemia

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 IT4B-ALL project word cloud

Explore the words cloud of the IT4B-ALL project. It provides you a very rough idea of what is the project "IT4B-ALL" about.

cog    first    malignant    preleukemic    ng2    escaping    dismal    preclinical    surface    proportion    monoclonal    relatively    ing    progenitors    marker    rapid    expression    epi173825514    losing    emerged    aggressiveness    valid    expressed    lineage    worse    consolidate    strategy    childhood    found    circumvent    trial    therapies    pressure    switch    erc    anti    cd34cd22cd19    mllr    infant    mll    ineffectual    antigens    germline    therapy    gmp    prognosis    refractory    infiltration    solely    car    academic    retained    antigen    cd19neg    clinical    efficacy    phasei    developmentally    glucocorticoid    cd19    massive    impressive    opposite    relapse    myeloid    protected    frequently    cd34    resistance    relapses    cancer    overarching    patent    commonest    earlier    car19    launch    pan    cell    cells    shown    immunotherapies    proof    cd22    rearrangements    therapeutic    cns    2014    immunotherapeutic    options    antibody    adult    subgroups    demonstration    respectively    representing    all    combined   

Project "IT4B-ALL" data sheet

The following table provides information about the project.

Coordinator		 FUNDACIO INSTITUT DE RECERCA CONTRA LA LEUCEMIA JOSEP CARRERAS 

Organization address
address: CARRER MUNTANER 383 3/2
city: BARCELONA
postcode: 8021
website: www.carrerasresearch.org

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.
 Coordinator Country Spain [ES]
 Total cost 150˙000 €
 EC max contribution 150˙000 € (100%)
 Programme 1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
 Code Call ERC-2018-PoC
 Funding Scheme ERC-POC
 Starting year 2019
 Duration (year-month-day) from 2019-01-01   to  2020-06-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    FUNDACIO INSTITUT DE RECERCA CONTRA LA LEUCEMIA JOSEP CARRERAS ES (BARCELONA) coordinator 150˙000.00

Map

 Project objective

B-ALL is the commonest cancer of childhood. There remain childhood B-ALL subgroups with dismal prognosis such as infant B-ALL and B-ALL carrying MLL rearrangements (MLLr). In addition, the prognosis of adult B-ALL is worse, and refractory/relapse (R/R) B-ALL remains dismal. CD19-targeted immunotherapies have emerged as promising therapeutic approaches for R/R B-ALL. CD19 CAR T-cells have shown impressive efficacy in R/R B-ALL. However, relatively rapid relapses are frequently observed, a proportion of them losing CD19 expression upon CAR19 T-cell therapy due to massive antigen pressure over CD19, resulting in a myeloid lineage switch in MLLr B-ALL, or the selection of CD19-/CD34 preleukemic progenitors. Further CD19-targeted therapy is thus ineffectual for CD19neg R/R B-ALL. Our overarching goal is to provide novel therapeutic options for (R/R) B-ALL.Targeting surface antigens whose expression, opposite to CD19, are commonly retained at relapse is a valid strategy to circumvent the loss of CD19 found in (R/R) B-ALL after CD19-targeted therapies. Recent work funded by my ERC-2014-CoG has identified NG2 and CD22 as key antigens to be targeted in (R/R) B-ALL. First, both antigens are retained in CD19neg R/R B-ALL. Second, NG2 is solely expressed in MLLr B-ALL, and is associated with CNS infiltration, aggressiveness and glucocorticoid resistance. Third, CD22 is a pan-B marker expressed developmentally earlier than CD19, and CD34CD22CD19- cells may represent pre-malignant progenitors escaping the CD19-targeted pressure. These results have just been protected by a European Patent (EPI173825514), and are the proof-of-principle demonstration of NG2 & CD22 representing promising immunotherapeutic targets, when combined with CD19 for both MLLr & MLL-germline B-ALL, respectively. Here we propose to consolidate preclinical work and GMP production of anti-NG2 monoclonal antibody and NG2/CD19 and CD22/CD19 CAR T-cells to launch a PhaseI academic clinical trial for R/R B-ALL

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "IT4B-ALL" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "IT4B-ALL" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.1.)

Back2theFuture (2020)

Back to the Future: Future expectations and actions in late medieval and early modern Europe, c.1400-c.1830

Read More  

HD-Neu-Screen (2020)

HD-MEA-based Neuronal Assays and Network Analysis for Phenotypic Drug Screenings

Read More  

HYDROGEN (2019)

HighlY performing proton exchange membrane water electrolysers with reinforceD membRanes fOr efficient hydrogen GENeration

Read More